Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N
Kunin-Lunenfeld Clinical Research Unit, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada.
Lancet. 1998 May 2;351(9112):1303-7. doi: 10.1016/s0140-6736(97)09528-7.
Tricyclic antidepressants (TCAs) are associated with an increased risk of falls and hip fractures in elderly people. Selective serotonin-reuptake inhibitors (SSRIs) are reported to be better tolerated than TCAs. We investigated the risk of hip fractures associated with SSRIs and TCAs.
This case-control study used administrative healthcare data from the province of Ontario, Canada. 8239 cases-patients aged 66 years or older, treated in hospital between April, 1994, and March, 1995, for hip fracture-were each matched for age and sex to five controls. Logistic regression was used to calculate the odds ratio for hip fracture with adjustment for potential confounding effects produced by concomitant drug use and comorbidity.
With participants who had no exposure to antidepressants as the reference category, the adjusted odds ratio for hip fracture was 2.4 (95% CI 2.0-2.7) for exposure to SSRIs, 2.2 (1.8-2.8) for exposure to secondary-amine TCAs, and 1.5 (1.3-1.7) for exposure to tertiary-amine TCAs. For all types of antidepressants, current use was associated with a higher risk of hip fracture than former use. The odds ratios for hip fracture were higher for new current users than for continuous current users in all three drug classes. The proportion of current use in the low-dose range was 22% for SSRIs, 50% for secondary-amine TCAs, and 58% for tertiary-amine TCAs.
Exposure to any of the three classes of antidepressants is associated with a significant increase in the risk of hip fracture. Despite differences in dose distribution, this analysis suggests that SSRIs do not offer an advantage over TCAs in terms of risk of hip fracture.
三环类抗抑郁药(TCA)与老年人跌倒及髋部骨折风险增加有关。据报道,选择性5-羟色胺再摄取抑制剂(SSRI)的耐受性优于TCA。我们调查了与SSRI和TCA相关的髋部骨折风险。
本病例对照研究使用了来自加拿大安大略省的行政医疗保健数据。8239例年龄在66岁及以上的病例——于1994年4月至1995年3月间在医院接受髋部骨折治疗的患者——均按照年龄和性别与五名对照进行匹配。采用逻辑回归计算髋部骨折的比值比,并对伴随用药和合并症产生的潜在混杂效应进行校正。
以未接触过抗抑郁药的参与者作为参照类别,接触SSRI的髋部骨折校正比值比为2.4(95%可信区间2.0 - 2.7),接触仲胺TCA的为2.2(1.8 - 2.8),接触叔胺TCA的为1.5(1.3 - 1.7)。对于所有类型的抗抑郁药,当前使用与髋部骨折风险高于既往使用相关。在所有三类药物中,新的当前使用者的髋部骨折比值比高于持续当前使用者。SSRI低剂量范围的当前使用比例为22%,仲胺TCA为50%,叔胺TCA为58%。
接触这三类抗抑郁药中的任何一种都与髋部骨折风险显著增加相关。尽管剂量分布存在差异,但该分析表明,在髋部骨折风险方面,SSRI并不比TCA更具优势。